Figure legends
Figure 1. Percentage of individuals with the 34 most common alterations. The bar graph represents the percentage of individuals with the most common molecular alterations. Frequently altered genes wereCDKN2A (30.8%, 4/13), TP53 (23.1%, 3/13), and MYC(15.4%, 2/13). Only genes with pathogenicity by FoundationOne® report is described. VUS is not involved.
Figure 2. Pie chart displaying the different types of alterations. Most of the alterations were single nucleotide variants (37.5%), followed by amplifications (27.0%).
Figure 3. Schematic showing pharmacological intervention according to actionable genomic alterations. At least one genetic aberration was detected in 11 patients (84.6%). Actionable mutations were discovered in 10 patients (76.9%), and seven patients (53.8%) had clinical trial candidates. No patients were able to receive biomarker-matched therapy. VUS, variant of uncertain significance.